ConductScience.org, home

Comparison · NCT00282438-sae

Autologous Hematopoietic Stem Cell Transplantation vs Allogeneic Stem Cell Transplantation: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Autologous Hematopoietic Stem Cell Transplantation vs Allogeneic Stem Cell Transplantation: serious adverse events. Trial comparisons, record NCT00282438-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00282438-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.793wilson
Risk in group 210.2071wilson
Risk difference, group 1 minus group 2-1-10.122newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one fewer participant with a serious adverse event on Autologous Hematopoietic Stem Cell Transplantation than on Allogeneic Stem Cell Transplantation1from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Autologous Hematopoietic Stem Cell TransplantationAutologous stem cells will be injected after conditioning~Autologous hematopoietic stem cell transplantation: Autologous hematopoietic stem cells will be injected after conditioning01EG000
Group 2Allogeneic Stem Cell TransplantationAllogeneic stem cells will be injected after conditioning~Allogeneic stem cell transplantation: Allogeneic stem cells will be injected after conditioning11EG001

Harm

What it counts
Total, serious adverse events
Time frame
Adverse event data was collected from time of first transplant 4/25/2012 until patient death 6/27/2015. Study closure effective 8/17/2015.

Source ClinicalTrials.gov

Trial

Title
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
NCT number
NCT00282438
Phases
PHASE1, PHASE2
Conditions
Sarcoidosis
Interventions
Autologous hematopoietic stem cell transplantation, Allogeneic stem cell transplantation
Lead sponsor
Northwestern University
Results first posted
2017-02-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00282438-sae